OTLK Faisal Ghiath Sukhtian bought Outlook Therapeutics, Inc. shares — SEC Form 4BUYOutlook Therapeutics, Inc.

OTLK has experienced extreme volatility, dropping 39.58% over the last 30 days and 24.54% in the past five days. The stock is currently trading 70.06% below its 52-week high of $3.39 and has surged 300.87% over the last 90 days.

• •Q3 2026 earnings report on August 14, 2026, as noted in the recent news.
• •Planned U.S. commercial launch of FDA-approved LYTENAVA for wet AMD, expected by year-end.
• •The company is preparing to sell 55.6 million common shares with warrants at a 10% discount, as reported on August 13, 2026.

• •The stock is currently trading at a 10% discount due to a planned sale of 55.6 million shares and warrants.
• •The company reported a Q3 loss and a revenue miss of -99.25% in its most recent earnings report.